Financial Summary (All financials)
In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
Revenues | 6,894.5 | 6,145.6 | 6,117.4 | 5,314.1 | 5,160.3 | 9,685.8 | 5,122.9 | 5,147.1 |
Revenue growth | 12.2% | 0.5% | 15.1% | 3.0% | -46.7% | 89.1% | -0.5% | 10.8% |
Cost of goods sold | 1,911.3 | 1,807.9 | 1,709.3 | 1,494.4 | 1,499.6 | 1,369.4 | 1,395.5 | 1,394.5 |
Gross profit | 4,983.2 | 4,337.7 | 4,408.1 | 3,819.7 | 3,660.7 | 8,316.4 | 3,727.4 | 3,752.6 |
Gross margin | 72.3% | 70.6% | 72.1% | 71.9% | 70.9% | 85.9% | 72.8% | 72.9% |
Sales and marketing | 98.6 | 83.3 | 135.6 | 134.8 | 121.8 | 114.8 | 115.4 | 112.1 |
General and administrative | 950.1 | 993.1 | 898.3 | 734.9 | 671.5 | 621.6 | 673.7 | 396.5 |
EBITA | 2,103.9 | 1,174.6 | 917.3 | 1,268.4 | 1,341.2 | 1,175.6 | 1,404.1 | 1,322.3 |
EBITA margin | 30.5% | 19.1% | 15.0% | 23.9% | 26.0% | 12.1% | 27.4% | 25.7% |
Amortization of intangibles | 62.9 | 62.5 | 52.7 | 29.7 | 17.4 | 13.9 | 10.6 | 12.6 |
EBIT | 2,041.0 | 1,112.1 | 864.6 | 1,238.7 | 1,323.8 | 1,161.7 | 1,393.5 | 1,309.7 |
EBIT margin | 29.6% | 18.1% | 14.1% | 23.3% | 25.7% | 12.0% | 27.2% | 25.4% |
Pre-tax income | 2,500.5 | 1,069.1 | 972.9 | 1,138.1 | 1,429.2 | 1,206.6 | 1,362.1 | 1,395.1 |
Income taxes | 531.1 | 261.6 | 235.1 | 255.0 | 268.2 | 338.3 | 398.0 | 390.6 |
Tax rate | 21.2% | 24.5% | 24.2% | 22.4% | 18.8% | 28.0% | 29.2% | 28.0% |
Earnings from continuing ops | 2,309.0 | 853.4 | 787.3 | 882.8 | 1,127.3 | 854.2 | 968.1 | 1,996.0 |
Earnings from discontinued ops | | | | | | | | -3.4 |
Net income | 2,309.0 | 853.4 | 787.3 | 882.8 | 1,127.3 | 854.2 | 968.1 | 1,992.6 |
Net margin | 33.5% | 13.9% | 12.9% | 16.6% | 21.8% | 8.8% | 18.9% | 38.7% |
|
Diluted EPS | $4.96 | $1.85 | $1.79 | $2.14 | $2.75 | $2.06 | $2.26 | $4.58 |
Shares outstanding (diluted) | 465.4 | 462.5 | 440.5 | 412.5 | 409.9 | 415.0 | 429.3 | 435.6 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|